TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02386436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
Study: NCT04047810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: 0.5- 2 million cells/kg, intravenously once
Study: NCT00095875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT03278184

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS sham motor cortex
Description: the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active prefrontal cortex stimulation
Description: the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active motor cortex stimulation
Description: the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
Study: NCT01490099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
Study: NCT04024033

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pine cone extract
Description: pine cone extract capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study: NCT05151081

Intervention type: OTHER
Intervention: basicly
Description: Do not repeat information already included in arm/group descriptions.
Study: NCT02681536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMG
Study: NCT00929175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active CPAP
Description: auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-CPAP
Description: The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
Study: NCT02227732

Intervention type: DEVICE
Group type: OTHER
Intervention: New Indwelling Pleural Catheter
Description: Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
Study: NCT04272840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Education
Description: Educational materials layering Glycemic Index education onto Canada's Food Guide and Diabetes Canada recommendations.
Study: NCT03410433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silk 4.0
Description: Silk suture 4.0

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PG 910 4.0
Description: PG 910 4.0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PP 4.0
Description: PP 4.0

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silk 5.0
Description: Silk 5.0

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PG910 5.0
Description: PG910 5.0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PP 5.0
Description: PP 5.0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APG 5.0
Description: APG 5.0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePTFE 5.0
Description: ePTFE 5.0
Study: NCT03075800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)
Description: The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
Study: NCT03426371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-140
Description: KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study: NCT01164774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace
Description: Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
Study: NCT01593293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PemCarbo
Description: Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pem only
Description: Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
Study: NCT00900458

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise training
Description: aerobic exercise training (cycling)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise training
Description: aerobic exercise training (cycling)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise training
Description: aerobic exercise training (cycling)
Study: NCT01417715

Intervention type: DEVICE
Intervention: Endomicroscopy
Description: Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.

Intervention type: DEVICE
Intervention: Endomicroscopy
Description: Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.

Intervention type: DEVICE
Intervention: Endomicroscopy
Description: Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.

Intervention type: DEVICE
Intervention: Endomicroscopy
Description: Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
Study: NCT00645814

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: 80 mg at Week 0 and 40 mg eow through Week 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg at Week 0 and 40 mg eow through Week 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg at Week 0 and 40 mg weekly through Week 11
Study: NCT03960775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline infusion during same time period.
Study: NCT03104699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: Anti-PD-1 Monoclonal Antibody
Study: NCT03529721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zumba dance fitness
Description: females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non zumba dance
Description: participants in this group will be doing their normal daily activities throughout the 8-week period.
Study: NCT02452905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Nitazoxanide)
Study: NCT01473238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation form
Description: A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation form
Description: A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
Study: NCT02369848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Lithoplasty System
Study: NCT01449461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets and capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets and capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets and capsules.
Study: NCT03181932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin inhalation powder
Description: 100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder
Description: 100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin inhalation powder
Description: In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
Study: NCT02928965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo with appearance of over - encapsulated minocycline
Study: NCT03252379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepaticojejunostomy
Description: * Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~* Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified hepaticojejunostomy with subcutaneous access loop
Description: In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified hepaticojejunostomy with gastric access loop
Description: * In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~* All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision.
Study: NCT01683357

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy.
Study: NCT02392624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab 300 mg administered SC Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab 300 mg administered SC Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to omalizumab administered SC Q4W.
Study: NCT00936715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally once daily
Study: NCT02518438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
Study: NCT01868997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teprotumumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT01449461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets and capsules.
Study: NCT03694886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Anhydrous with small sucrose pill
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - large sucrose pill
Description: sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Anhydrous with large sucrose pill
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - small sucrose pill
Description: sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
Study: NCT01193244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Study: NCT02263027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Licensed trivalent inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Licensed trivalent inactivated influenza vaccine
Study: NCT02683577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telotristat etiprate
Study: NCT03891381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tetragraph quantitative monitoring
Description: Neuromuscular monitoring will be guided by information provided by the Tetragraph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetragraph quantitative monitoring
Description: Neuromuscular monitoring will be guided by information provided by the Tetragraph
Study: NCT01601548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cancer Recovery
Description: Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment